5Tran JH,Jacoby GA,Hooper DC.The plasmid-mediated protein Qnr protects topoisomerase Ⅳ from ciprofloxacin inhibition and interacts with the ParE subunit[A].Abstr Intersci Conf Antimicrob Agents Chemother,2003.43:abstract No.C1-604.
6Tran JH,Jacoby GA,Hooper DC.Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase[J].Antimicrob Agents Chemother,2005,49(1):118-125.
7Tran JH,Jacoby GA,Hooper DC.Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase Ⅳ[J].Antimicrob Agents Chemother,2005,49(7):3050-3052.
8Jacoby GA,Chow N,Waites KB.Prevalence of plasmid-mediated quinolone resistance[J].Antimicrob Agents Chemother,2003,47(2):559-562.
9Wang M,Sahm DF,Jacoby GA,et al.Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States[J].Antimicrob Agents Chemother,2004,48(4):1295-1299.
10Rodriguez-Martinez JM,Pascual A,Garcia I.Detection of the plasmid-mediated quinolone resistance determinant qnr among clinical isolates of Klebsiella pneumoniae producing AmpC-type beta-lactamase[J].J Antimicrob Chemother,2003,52(4):703-706.
二级参考文献19
1Quale J,Landman D,Saurina G, et al. Manipulation of a hospital antimicrobial fomnulary to control an outbreak of vancomycin resistant enterococci. Clin Infect Dis, 1996,23 : 1020.
2National Committee for Clinical Laboratory Standards.Performance standards for antimicrobial susceptiblity tesing [S]. Fourteenth informational supplement M100-S14. NCCLS, 2004,24:30-35.
3Luis MM, Alvaro P, George AJ. Quinolone resistance from a transferable plasmid [J]. The Lancet, 1998,351: 797-799.
4Minggui W, Daniel FS, George AJ, et al. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States [J]. Antimicrob Agents Chemother, 2004, 48:1295-1299.
5Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
6Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.
7Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in gram-negative isolates from ICU in Turkey:analysis of data from the last 5 years. J Chemother, 2002, 14:140-146.
8Karlowsky JA, Kelly LJ, Thornsberry C , et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000:TRUST and TSN data for the United States. J Autimicrob Agents , 2002,19: 21-31.
9National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. National Committee for Clinical Laboratory Standards,Wayne, Pa.2002,1.
10Chanawong A. M' Zali FH, Heritage J, et al. Three cefotaximases,CTX-M-9, CTX-M-13, CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother, 2002, 46:630-637.
